Brooks Laboratories Limited (BROOKS) fundamentals
Brooks Laboratories Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as BROOKS (ISIN INE650L01011). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Brooks Laboratories Limited does
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company working on a contract basis. The Company’s segment is Pharmaceutical products, including ingredients and intermediaries. It manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup, and eye/ear drops. Its products under the Carbapenem category are Imipenem 250 (Milligram) mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, and Doripenem 500mg. It offers Penicillins in the form of injections, tablets, and dry syrup. Its general category of products includes liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, Iron sucrose 50mg/2.5ml, Phenytoin sodium 50mg/ml and others. Its dry powder injections include Artesunate 60mg, Artesunate 120mg, Omeprazole 40mg, Rabeprazole 20mg, Pantoprazole 40mg and others.
Valuation and market data
| Last close | ₹66.38 |
|---|---|
| Market capitalisation | ₹195 crore |
| Enterprise value | ₹193 crore |
| P/E (TTM) | 7.95 |
| Price to book | 1.59 |
| Price to sales (TTM) | 1.31 |
| Book value per share | ₹41.67 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Sep 05 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹87 crore | ₹6 crore | ₹6 crore | 1.97 |
| Mar 2025 | ₹83 crore | ₹3 crore | ₹3 crore | 1.14 |
| Mar 2024 | ₹80 crore | ₹2 crore | ₹2 crore | 0.58 |
| Mar 2023 | ₹56 crore | ₹-8 crore | ₹-8 crore | -3.32 |
| Mar 2022 | ₹78 crore | ₹1 crore | ₹1 crore | 0.27 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 52.6% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 9.9% |
| Other domestic institutions | 0.5% |
| Retail and others | 37.0% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.